COLORADO
Study: Liposomal clodronate in canine cancer.
Location: Colorado State University Animal Cancer Center, Fort Collins, CO
Phone: 970-297-4195
www.csuanimalcancercenter.org
Eligibility: In general, these studies are available to qualifying patients living within 100 miles of the Animal Cancer Center
at Colorado State University. Dogs with biopsy-confirmed cancers (excluding mast cell tumor, hemangiosarcoma, and
malignant histiocytosis) are potentially eligible for this study. The tumor must be less than 8 cm (approximately 3.5
inches) in diameter and located in an easily accessible area for biopsy. Dogs must have good function of liver and
kidneys and acceptable blood-cell counts. They must be free of severe underlying disease. Prior treatment is
acceptable, with a 72-hour withdrawal from corticosteroids (such as prednisone), a 3-week withdrawal from prior
chemotherapy, and a 6-week withdrawal from prior radiation therapy. Owners must consent to a postmortem examination
(autopsy) at the time their pet dies or is euthanized.
Summary: Macrophages are immune cells that normally scavenge and clear a variety of substances (such as cell debris,
bacteria, and foreign materials) from the body. Liposomes are tiny, spherical particles of lipids (a group of compounds
that contain fats or oils) that are used to deliver various drugs in the body. Clodronate is a medication in the
bisphosphonate class of drugs. Bisphosphonates are used in the treatment of osteoporosis in people and in bone
cancer in people and dogs. Previous research found that liposomal clodronate was an effective agent against
macrophages. Liposomal clodronate is used to decrease the number of tumor-associated macrophages. The presence
of these macrophages in tumors has been associated with increased tumor growth and spread of the cancer (known as
metastasis ). Potentially, liposomal clodronate could be used to treat many different types of tumors. The goals of this
study are to demonstrate liposomal clodronate as a safe and effective cancer therapy and to determine the anti-tumor
activity of liposomal clodronate against a variety of canine tumors.
Requirements and Incentives: The owner is financially responsible for costs associated with the diagnosis and staging of
the disease (such as blood tests, chest X-rays, biopsy) to determine the pet s eligibility for enrollment in this study. In
addition, the owner is responsible for the recheck examination fee for each visit during the study and any additional
diagnostic tests recommended by the pet s oncology clinician. The owner is expected to make and keep all appointments
according to the study protocol. Once enrolled, the study will pay for the costs of study-related blood work and biopsies
and the cost of the liposomal clodronate.
ILLINOIS
Study: Evaluation of the procaspase-3 activator PAC-1 in dogs with neoplasia
Location: University of Illinois Cancer Care Clinic, Urbana, IL
Phone: (217) 244-0194; (217) 244-0537; (217) 244-7789
http://www.cvm.uiuc.edu/vth/MedServices/ClinicalTrial/PDF/Oncology/EvaluationProcaspaseDog.pdf
Eligibility:: Dogs with histologically or cytologically confirmed neoplasia. Dogs must have a measurable tumor burden.
Dogs must have a favorable performance status. NO concurrent chemotherapy or radiation therapy. Dogs must be off of
all such therapy for 1 week prior to study enrollment. Both newly diagnosed dogs and those with recurrent disease are
eligible. Signed informed owner consent; all treatment options for the pet will be presented and owner must decline all
other options. NO significant co-morbid illness, which includes renal or hepatic failure, history of congestive heart failure
or clinical coagulopathy. Dogs must weight > or = 20 kg.
Purpose of study: Caspase-3 is a cell enzyme that directly leads to cell death. Cancer cells seem to have higher levels of
this enzyme compared to normal cells. PAC-1 is a novel compound which leads to activation of this enzyme, thereby
causing cell death in cancer cells and sparing normal cells. The goal of the first phase of this trial is to identify a safe,
relevant dose of PAC-1 for tumor bearing dogs. This will be achieved by treating dogs for 7 days with oral PAC-1 and
evaluating biologic effects by appropriate surrogate markers.
Diagnostics and Treatment: Diagnostics include: 1) Screening bloodwork and urinalysis, 2) thoracic radiographs, 3)
abdominal ultrasound, 4) tumor biopsy and histopathology, 5) bone marrow aspirate and cytology under sedation on day
7. All dogs will be treated with a 7-day course of oral PAC-1.
Compensation: The study will pay for all diagnostics needed during the two week course of the study, an equivalent total
compensation of ~$1300. Please feel free to call Dr. Laura Garrett at (217)244-0194, Dr. Pam Lucas at (217)244-0537,
or Nancy George at (217)244-7789 to refer a patient or for any additional information. Referring veterinarian and client
calls are welcome.
MISSOURI
Study: Evaluation of Satraplatin
Location: Missouri University Veterinary Medical Teaching Hospital, Columbia, MO
Phone: 573-882-7821.
http://www.cvm.missouri.edu/oncology/current.html
Eligibility: Any tumor, including lymphoma confirmed by histopatholgy or cytology. Normal CBC, renal and liver function
and UA at first visit owner pays.Thoracic radiographs. NO steroids or NSAIDS
Summary: Satraplatin is similar to other drugs used for various cancer types but is the first of its kind to be administered
as a capsule by mouth.
Benefit: Free drug to owner. Owner pays for initial workup and follow-up bloodwork (CBC’s – Day 14, 1,2,3,4 and 6
months) Chemistry panel-6 months, Rads- 3 & 6 months Follow up bloodwork can be performed at the RDVM and drug
will be supplied as long as results are sent to VMTH.
Study: Evaluation of SPI-1620
Location: Missouri University Veterinary Medical Teaching Hospital, Columbia, MO
Phone: (573) 882-7821
http://www.cvm.missouri.edu/oncology/trialscurrent.htm
Eligibility: Solid tumors accessible for blood flow measurements. Patients are NOT eligible if they have: renal
insufficiency, coagulapathies, uncontrolled hypo or hypertension, respiratory disease, cardiac dysfunction or brain
metastasis. CBC, chemistry panel, PT/PTT, UA, BP and chest rads first visit owner pays
Summary: SPI-1620 is an endothelin B agonist and is being given to dogs with solid tumors that are receiving
chemotherapy. Tumors must be located in the subcutaneous tissue or be otherwise superficially located to allow blood
flow measurements. SPI-1620 is given intravenously, overnight stay in ICU. Required visits: Day 7 (repeat SPI-1620
followed by standard chemo), and Day 14
Benefit: Study covers cost of drug, chemo, follow-up visits and $500.00 at end of study towards other therapy options or
continued therapy with SPI-1620.
WISCONSIN
Study: NOVEL DRUG FOR THE TREATMENT OF DOGS WITH MEASURABLE MALIGNANT TUMORS
Location: University of Wisconsin, Madison WI
http://www.vetmed.wisc.edu/data/news/trials.html
Eligibility: Measurable malignant tumors
Purpose of study: The purpose of this study is to evaluate a novel drug analog that has been shown to have anticancer
activity against canine tumor cells in laboratory experiments. The maximum well-tolerated dose of these drugs has been
determined from studies in normal dogs and in pet dogs with cancer. The goal of this study is to evaluate the antitumor
activity of these drugs in dogs with malignant tumors.
Requirements and Incentives: Clients participating in this study will be given special financial considerations. Specifically,
the owner is responsible for the cost of diagnosing and staging their dog's cancer prior to entering the studY
(approximately $700). The study will pay for all costs related to study drug treatment and follow-up evaluations and there
is an additional financial incentive ($1,000 VMTH credit) for owners once their dog is entered into this study.�
Additionally, the cost of treating significant side-effects from these drugs, if they were to occur, will be defrayed (up to
$3,000).
Study: Liposomal clodronate in canine cancer.
Location: Colorado State University Animal Cancer Center, Fort Collins, CO
Phone: 970-297-4195
www.csuanimalcancercenter.org
Eligibility: In general, these studies are available to qualifying patients living within 100 miles of the Animal Cancer Center
at Colorado State University. Dogs with biopsy-confirmed cancers (excluding mast cell tumor, hemangiosarcoma, and
malignant histiocytosis) are potentially eligible for this study. The tumor must be less than 8 cm (approximately 3.5
inches) in diameter and located in an easily accessible area for biopsy. Dogs must have good function of liver and
kidneys and acceptable blood-cell counts. They must be free of severe underlying disease. Prior treatment is
acceptable, with a 72-hour withdrawal from corticosteroids (such as prednisone), a 3-week withdrawal from prior
chemotherapy, and a 6-week withdrawal from prior radiation therapy. Owners must consent to a postmortem examination
(autopsy) at the time their pet dies or is euthanized.
Summary: Macrophages are immune cells that normally scavenge and clear a variety of substances (such as cell debris,
bacteria, and foreign materials) from the body. Liposomes are tiny, spherical particles of lipids (a group of compounds
that contain fats or oils) that are used to deliver various drugs in the body. Clodronate is a medication in the
bisphosphonate class of drugs. Bisphosphonates are used in the treatment of osteoporosis in people and in bone
cancer in people and dogs. Previous research found that liposomal clodronate was an effective agent against
macrophages. Liposomal clodronate is used to decrease the number of tumor-associated macrophages. The presence
of these macrophages in tumors has been associated with increased tumor growth and spread of the cancer (known as
metastasis ). Potentially, liposomal clodronate could be used to treat many different types of tumors. The goals of this
study are to demonstrate liposomal clodronate as a safe and effective cancer therapy and to determine the anti-tumor
activity of liposomal clodronate against a variety of canine tumors.
Requirements and Incentives: The owner is financially responsible for costs associated with the diagnosis and staging of
the disease (such as blood tests, chest X-rays, biopsy) to determine the pet s eligibility for enrollment in this study. In
addition, the owner is responsible for the recheck examination fee for each visit during the study and any additional
diagnostic tests recommended by the pet s oncology clinician. The owner is expected to make and keep all appointments
according to the study protocol. Once enrolled, the study will pay for the costs of study-related blood work and biopsies
and the cost of the liposomal clodronate.
ILLINOIS
Study: Evaluation of the procaspase-3 activator PAC-1 in dogs with neoplasia
Location: University of Illinois Cancer Care Clinic, Urbana, IL
Phone: (217) 244-0194; (217) 244-0537; (217) 244-7789
http://www.cvm.uiuc.edu/vth/MedServices/ClinicalTrial/PDF/Oncology/EvaluationProcaspaseDog.pdf
Eligibility:: Dogs with histologically or cytologically confirmed neoplasia. Dogs must have a measurable tumor burden.
Dogs must have a favorable performance status. NO concurrent chemotherapy or radiation therapy. Dogs must be off of
all such therapy for 1 week prior to study enrollment. Both newly diagnosed dogs and those with recurrent disease are
eligible. Signed informed owner consent; all treatment options for the pet will be presented and owner must decline all
other options. NO significant co-morbid illness, which includes renal or hepatic failure, history of congestive heart failure
or clinical coagulopathy. Dogs must weight > or = 20 kg.
Purpose of study: Caspase-3 is a cell enzyme that directly leads to cell death. Cancer cells seem to have higher levels of
this enzyme compared to normal cells. PAC-1 is a novel compound which leads to activation of this enzyme, thereby
causing cell death in cancer cells and sparing normal cells. The goal of the first phase of this trial is to identify a safe,
relevant dose of PAC-1 for tumor bearing dogs. This will be achieved by treating dogs for 7 days with oral PAC-1 and
evaluating biologic effects by appropriate surrogate markers.
Diagnostics and Treatment: Diagnostics include: 1) Screening bloodwork and urinalysis, 2) thoracic radiographs, 3)
abdominal ultrasound, 4) tumor biopsy and histopathology, 5) bone marrow aspirate and cytology under sedation on day
7. All dogs will be treated with a 7-day course of oral PAC-1.
Compensation: The study will pay for all diagnostics needed during the two week course of the study, an equivalent total
compensation of ~$1300. Please feel free to call Dr. Laura Garrett at (217)244-0194, Dr. Pam Lucas at (217)244-0537,
or Nancy George at (217)244-7789 to refer a patient or for any additional information. Referring veterinarian and client
calls are welcome.
MISSOURI
Study: Evaluation of Satraplatin
Location: Missouri University Veterinary Medical Teaching Hospital, Columbia, MO
Phone: 573-882-7821.
http://www.cvm.missouri.edu/oncology/current.html
Eligibility: Any tumor, including lymphoma confirmed by histopatholgy or cytology. Normal CBC, renal and liver function
and UA at first visit owner pays.Thoracic radiographs. NO steroids or NSAIDS
Summary: Satraplatin is similar to other drugs used for various cancer types but is the first of its kind to be administered
as a capsule by mouth.
Benefit: Free drug to owner. Owner pays for initial workup and follow-up bloodwork (CBC’s – Day 14, 1,2,3,4 and 6
months) Chemistry panel-6 months, Rads- 3 & 6 months Follow up bloodwork can be performed at the RDVM and drug
will be supplied as long as results are sent to VMTH.
Study: Evaluation of SPI-1620
Location: Missouri University Veterinary Medical Teaching Hospital, Columbia, MO
Phone: (573) 882-7821
http://www.cvm.missouri.edu/oncology/trialscurrent.htm
Eligibility: Solid tumors accessible for blood flow measurements. Patients are NOT eligible if they have: renal
insufficiency, coagulapathies, uncontrolled hypo or hypertension, respiratory disease, cardiac dysfunction or brain
metastasis. CBC, chemistry panel, PT/PTT, UA, BP and chest rads first visit owner pays
Summary: SPI-1620 is an endothelin B agonist and is being given to dogs with solid tumors that are receiving
chemotherapy. Tumors must be located in the subcutaneous tissue or be otherwise superficially located to allow blood
flow measurements. SPI-1620 is given intravenously, overnight stay in ICU. Required visits: Day 7 (repeat SPI-1620
followed by standard chemo), and Day 14
Benefit: Study covers cost of drug, chemo, follow-up visits and $500.00 at end of study towards other therapy options or
continued therapy with SPI-1620.
WISCONSIN
Study: NOVEL DRUG FOR THE TREATMENT OF DOGS WITH MEASURABLE MALIGNANT TUMORS
Location: University of Wisconsin, Madison WI
http://www.vetmed.wisc.edu/data/news/trials.html
Eligibility: Measurable malignant tumors
Purpose of study: The purpose of this study is to evaluate a novel drug analog that has been shown to have anticancer
activity against canine tumor cells in laboratory experiments. The maximum well-tolerated dose of these drugs has been
determined from studies in normal dogs and in pet dogs with cancer. The goal of this study is to evaluate the antitumor
activity of these drugs in dogs with malignant tumors.
Requirements and Incentives: Clients participating in this study will be given special financial considerations. Specifically,
the owner is responsible for the cost of diagnosing and staging their dog's cancer prior to entering the studY
(approximately $700). The study will pay for all costs related to study drug treatment and follow-up evaluations and there
is an additional financial incentive ($1,000 VMTH credit) for owners once their dog is entered into this study.�
Additionally, the cost of treating significant side-effects from these drugs, if they were to occur, will be defrayed (up to
$3,000).
General cancer
| PET CANCER CENTER Comprehensive guide to cancer diagnosis and treatment in cats and dogs |
Please take our short survey to help us understand pet owners' perception of clinical trials.
© 2007 Pet Cancer Center. ALL RIGHTS RESERVED.
Last updated 11/9/09
Clinical trials for any type of cancer in dogs
Please make a donation to support our goals of funding veterinary cancer research and
continuing to provide free online resources for pet owners
continuing to provide free online resources for pet owners